Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06730659
PHASE1
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Sponsor: Tianjin Medical University Cancer Institute and Hospital
View on ClinicalTrials.gov
Summary
Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.
Official title: A Single-Arm, Open-Label, Phase I Study of CHT101 for CD70-Positive Relapsed/Refractory Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2024-04-19
Completion Date
2039-04-18
Last Updated
2024-12-12
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
CHT101
CHT101: CD 70 UCAR T
Locations (1)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China